Endo Purchases Somar Of Mexico City

By

Endo International plc, with headquarters in Malvern and Dublin, Ireland, has just acquired Grupo Farmaceutico Somar, a leading, privately owned specialty pharmaceuticals company based in Mexico City.

Endo is focused on transforming itself into a global specialty healthcare company, and has its eye on emerging markets in Latin America. Endo executives say Somar has a proven commercial organization, scalable manufacturing facilities and a robust portfolio of current products.

Also attractive to Endo, Somar has more than 60 new products in the pipeline to be launched in the next three years.

The company has not released purchase price information.

Norbert Oppitz (Courtesy of www.labmate-online.com
Norbert Oppitz (Courtesy of www.labmate-online.com)

Endo also appointed Norbert Oppitz  regional president for Latin America, Africa and export markets, effective Oct.1.  Oppitz will assume responsibility for Endo’s business in Mexico, including Somar, and oversee Endo’s investment in Litha Healthcare, based in South Africa.  Oppitz has 25 years of global pharmaceutical leadership experience and most recently had a leadership position at Takeda Pharmaceuticals, Latin America.

“The successful acquisition of Somar supports our strategy for growth and creates a substantial presence for Endo in the exciting and growing Latin American market,” said Rajiv De Silva, Endo president and CEO. “Together with the addition of Norbert to our leadership team I believe we are well positioned to meet the evolving needs of the patients we serve while creating value for our shareholders.”

Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Its drugs are for pain management, endocrinology and oncology uses.

______

7.28.2014 Twitter  Follow us on Twitter

7.28.2014 Facebook  Like us on Facebook

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo